Novel Treatments for Idiopathic Pulmonary Fibrosis

American Journal of Medicine

Volumn 128, Issue 5, 2015, Pages 447-449

  Spagnolo, Paolo ^a,b  

^a Medical University Clinic   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; PIRFENIDONE; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE; PYRIDONE DERIVATIVE;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FATALITY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; FUNCTIONAL DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LUNG PARENCHYMA; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; UNITED STATES; ANTAGONISTS AND INHIBITORS; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PROTEIN-TYROSINE KINASES; PYRIDONES;

EID: 84928942892     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.01.003     Document Type: Editorial

References (16)

1. G. Raghu, H.R. Collard, and J.J. Egan et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
2. T.E. King Jr., A. Pardo, and M. Selman Idiopathic pulmonary fibrosis Lancet 378 2011 1949 1961
3. G. Raghu, S.-Y. Chen, and W.-S. Yeh et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence and survival, 2001-11 Lancet Respir Med 2 2014 566 572
4. V. Navaratnam, K.M. Fleming, and J. West et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K Thorax 66 2011 462 467
5. P. Spagnolo, C. Del Giovane, and F. Luppi Non-steroid agents for idiopathic pulmonary fibrosis Cochrane Database Syst Rev 9 2010 CD003134
6. P.W. Noble, C. Albera, and W.Z. Bradford et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
7. T.E. King Jr., W.Z. Bradford, and S. Castro-Bernardini et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2014 2083 2092
8. L. Richeldi, R.M. du Bois, and G. Raghu et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2014 2071 2082
9. H. Taniguchi, M. Ebina, and Y. Kondoh et al. Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 35 2010 821 829
10. H.R. Collard, T.E. King, B.B. Bartelson, J.S. Vourlekis, M.I. Schwarz, and K.K. Brown Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 168 2003 538 542
11. R.M. du Bois, D. Weycker, and C. Albera et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 184 2011 459 466
12. N.I. Chaudhary, G.J. Roth, and F. Hilberg et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur Respir J 29 2007 976 985
13. T.E. King, C. Albera, and W.Z. Bradford et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials Am J Respir Crit Care Med 189 2014 825 831
14. G.M. Hunninghake, H. Hatabu, and Y. Okajima et al. MUC5B promoter polymorphism and interstitial lung abnormalities N Engl J Med 368 2013 2192 2200
15. R.K. Putman, I.O. Rosas, and G.M. Hunninghake Genetics and early detection in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 189 2014 770 778
16. P. Spagnolo, R.M. du Bois, and V. Cottin Rare lung disease and orphan drug development Lancet Respir Med 1 2013 479 487